Tax Management India. Com
Law and Practice  :  Digital eBook
Research is most exciting & rewarding
  TMI - Tax Management India. Com
Follow us:
  Facebook   Twitter   Linkedin   Telegram

TMI Blog

Home

1986 (10) TMI 254

X X   X X   Extracts   X X   X X

→ Full Text of the Document

X X   X X   Extracts   X X   X X

..... . - The question for decision in this appeal by the Collector of Central Excise, Bombay-II is whether respondents manufacture Dimethyl Sulphate is eligible for exemption under Notification 55/75-C.E., dated 1-3-1975 as drug intermediate. 2. The Central Government in exercise of powers conferred by sub-rule (1) of Rule 8 of the Central Excise Rules, 1944 published notification March 1, 1975 p .....

X X   X X   Extracts   X X   X X

→ Full Text of the Document

X X   X X   Extracts   X X   X X

..... anufacture of final products. He held that in view of this position the product did not merit consideration as drug intermediate and no exemption as required could be granted. In appeal, however, the Collector of Central Excise (Appeals), Bombay by his order dated 21-3-1983 found in favour of the respondents and the product eligible for exemption under the notification. He accordingly allowed the .....

X X   X X   Extracts   X X   X X

→ Full Text of the Document

X X   X X   Extracts   X X   X X

..... e by the Govt. of India in the case of Hindustan Organic Chemicals Ltd. [1982 (10) E.L.T. 721]. Besides this, High Court of Judicature at Bombay in Rakesh Enterprises Another v. Union of India Another - 1986 (25) E.L.T. 906 (Bombay), to which our attention has been drawn by the respondents, has held that it is impossible to accede to the submission of the Department that apart from the product .....

X X   X X   Extracts   X X   X X

→ Full Text of the Document

X X   X X   Extracts   X X   X X

..... hich shows that the product would appear to be drug intermediate in respect of certain drugs, the appellant s only argument is that because the product is a methylating agent and is not found in the end-product it would not merit treatment as drug intermediate. In view of the precedents referred to above, we feel that such a contention is not acceptable. We, therefore, dismiss this appeal. - .....

X X   X X   Extracts   X X   X X

→ Full Text of the Document

X X   X X   Extracts   X X   X X

 

 

 

 

Quick Updates:Latest Updates